Published in Int J Cancer on June 15, 1983
Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol (1988) 16.82
Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A (1992) 3.61
The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. Stat Med (1999) 3.53
Relationship between Energy-dependent Phosphate Uptake and the Electrical Membrane Potential in Lemna gibba G1. Plant Physiol (1981) 3.03
Fraud in medical research: an international survey of biostatisticians. ISCB Subcommittee on Fraud. Control Clin Trials (2000) 2.67
Familial granulomatous arthritis (Blau syndrome) with granulomatous renal lesions. J Pediatr (1998) 2.27
SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci (1999) 2.21
Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae. J Exp Med (1998) 2.19
Deregulated c-fos expression interferes with normal bone development in transgenic mice. Nature (1987) 2.08
IL-8 in septic shock, endotoxemia, and after IL-1 administration. J Immunol (1991) 2.03
Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med (1993) 2.03
Risk from low-dose exposures. Science (1994) 1.99
Alcohol and drug disorders among physically abusive and neglectful parents in a community-based sample. Am J Public Health (1994) 1.96
A recombinant Chlamydia trachomatis major outer membrane protein binds to heparan sulfate receptors on epithelial cells. Proc Natl Acad Sci U S A (1996) 1.87
Reduced postoperative pancreatic fistula rate after pancreatogastrostomy versus pancreaticojejunostomy. J Gastrointest Surg (2008) 1.83
Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol (1993) 1.73
Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity. J Neurosurg (1996) 1.65
Hypothermia during elective abdominal aortic aneurysm repair: the high price of avoidable morbidity. J Vasc Surg (1995) 1.64
High-risk intrahospital transport of critically ill patients: safety and outcome of the necessary "road trip". Crit Care Med (1995) 1.54
Effects of acid-base correction on hemodynamics, oxygen dynamics, and resuscitability in severe canine hemorrhagic shock. Crit Care Med (1994) 1.54
Latent chromosomal instability in cancer patients. Hum Genet (1997) 1.51
Multimodal imaging of pancreatic beta cells in vivo by targeting transmembrane protein 27 (TMEM27). Diabetologia (2012) 1.51
Improvement of immune functions in HIV infection by sulfur supplementation: two randomized trials. J Mol Med (Berl) (2000) 1.50
Phenotypic and genotypic characteristics of a cell line from a squamous cell carcinoma of human skin. J Natl Cancer Inst (1982) 1.49
Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastasis formation in vivo. Int J Cancer (1979) 1.48
Effects of intravenous IL-8 administration in nonhuman primates. J Immunol (1992) 1.44
Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion. J Exp Med (1991) 1.44
Acute acalculous cholecystitis. J Am Coll Surg (1995) 1.43
Preservation of morphological, functional, and karyotypic traits during long-term culture and in vivo passage of two human skin squamous cell carcinomas. Cancer Res (1983) 1.42
Effects of pentoxifylline on hemodynamics, oxygen transport, and tissue metabolism in experimental, severe hemorrhagic shock. Crit Care Med (1991) 1.41
Genetics and regulation of chitobiose utilization in Borrelia burgdorferi. J Bacteriol (2001) 1.41
c-fos expression induces bone tumors in transgenic mice. Oncogene (1989) 1.40
Detection of mutations in the DNA polymerase delta gene of human sporadic colorectal cancers and colon cancer cell lines. Int J Cancer (1999) 1.38
Descending aortic cannulation during emergent thoracotomy for blunt traumatic cardiac arrest. J Trauma (1999) 1.38
Growth and differentiation characteristics of transformed keratinocytes from mouse and human skin in vitro and in vivo. J Invest Dermatol (1983) 1.36
Ultrastructural analysis of developmental events in Chlamydia pneumoniae-infected cells. Infect Immun (2000) 1.34
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer (2007) 1.33
Modeling cancer detection: tumor size as a source of information on unobservable stages of carcinogenesis. Math Biosci (2001) 1.30
A ninth complementation group in xeroderma pigmentosum, XP I. Mutat Res (1985) 1.26
Inhibition of lymphocyte proliferation by factor(s) produced by Schistosoma mansoni. Eur J Immunol (1977) 1.24
Elongation factor Tu resistant to kirromycin in an Escherichia coli mutant altered in both tuf genes. Proc Natl Acad Sci U S A (1977) 1.22
Pollen-based quantitative reconstructions of Holocene regional vegetation cover (plant-functional types and land-cover types) in Europe suitable for climate modelling. Glob Chang Biol (2014) 1.21
Preparation of the FhuA (TonA) receptor protein from cell envelopes of an overproducing strain of Escherichia coli K-12. J Bacteriol (1986) 1.20
Occupational disease in New York State: a comprehensive examination. Am J Ind Med (1989) 1.19
The expression of the imprinted genes H19 and IGF-2 in choriocarcinoma cell lines. Is H19 a tumor suppressor gene? Oncogene (1997) 1.18
Characterization of BSp73, a spontaneous rat tumor and its in vivo selected variants showing different metastasizing capacities. Invasion Metastasis (1983) 1.17
Parathyroid hormone-related protein and its receptors: nuclear functions and roles in the renal and cardiovascular systems, the placental trophoblasts and the pancreatic islets. Br J Pharmacol (2001) 1.15
The product of the imprinted H19 gene is an oncofetal RNA. Mol Pathol (1997) 1.15
Mechanisms involved in the intrinsic isoniazid resistance of Mycobacterium avium. Mol Microbiol (1998) 1.14
Modulation of DNA polymerases alpha, delta and epsilon by lactate dehydrogenase and 3-phosphoglycerate kinase. Biochim Biophys Acta (1998) 1.14
Intestinal sugar transport in experimental diabetes. Diabetes (1981) 1.13
Inhibition of fusion of Chlamydia trachomatis inclusions at 32 degrees C correlates with restricted export of IncA. Infect Immun (2002) 1.12
Improving biological control by combining biocontrol agents each with several mechanisms of disease suppression. Phytopathology (2002) 1.12
Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer: a phase II trial. Eur J Cancer (2002) 1.11
Induction of cell-associated interleukin 1 through stimulation of the adhesion-promoting proteins LFA-1 (CD11a/CD18) and CR3 (CD11b/CD18) of human monocytes. Eur J Immunol (1990) 1.11
[Arrhythmias and symptoms during long-term ECG in ambulatory patients]. Schweiz Rundsch Med Prax (1984) 1.09
The elongation factor Tu binds aminoacyl-tRNA in the presence of GDP. J Biol Chem (1982) 1.09
Terrestrial and aquatic mammals of the Pantanal. Braz J Biol (2011) 1.08
Chlamydia pneumoniae major outer membrane protein is a surface-exposed antigen that elicits antibodies primarily directed against conformation-dependent determinants. Infect Immun (2001) 1.08
Ligand/receptor binding for 2,3,7,8-TCDD: implications for risk assessment. Fundam Appl Toxicol (1993) 1.08
Evaluation of historical control data in carcinogenicity studies. Hum Exp Toxicol (2003) 1.06
p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res (2001) 1.05
Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer. Br J Cancer (2009) 1.03
Reconstructing 3-D light-microscopic images by digital image processing. Appl Opt (1985) 1.03
Natural autoantibodies and complement promote the uptake of a self antigen, human thyroglobulin, by B cells and the proliferation of thyroglobulin-reactive CD4(+) T cells in healthy individuals. Eur J Immunol (2001) 1.01
Deficiency of the adhesive protein complex lymphocyte function antigen 1, complement receptor type 3, glycoprotein p150,95 in a girl with recurrent bacterial infections. Effects on phagocytic cells and lymphocyte functions. J Clin Invest (1985) 1.01
Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. Pharmacogenetics (2001) 1.00
Effect of glutathione depletion and oral N-acetyl-cysteine treatment on CD4+ and CD8+ cells. FASEB J (1994) 1.00
[Analytical characterization of palatinit (author's transl)]. Z Lebensm Unters Forsch (1979) 1.00
Modeling the number and size of hepatic focal lesions following exposure to 2,3,7,8-TCDD. Toxicol Appl Pharmacol (1996) 0.99
Dose-response analysis of the enhancement of liver tumour formation in CF-1 mice by dieldrin. Carcinogenesis (1982) 0.99
Risk characterisation of chemicals in food and diet. Food Chem Toxicol (2003) 0.99
Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs (2010) 0.98
Functional role of the alpha-chain of complement receptor type 3 in human eosinophil-dependent antibody-mediated cytotoxicity against schistosomes. J Immunol (1987) 0.98
Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c. Scand J Immunol (1988) 0.98
A replicated association between polymorphisms near TNFα and risk for adverse reactions to radiotherapy. Br J Cancer (2012) 0.98
Activated skin mast cells are involved in murine hair follicle regression (catagen). Lab Invest (1997) 0.98
Blood transfusion-induced suppression of cellular immunity in man. Hum Immunol (1980) 0.98
Characterization of the human glomerular C3 receptor as the C3b/C4b complement type one (CR1) receptor. J Immunol (1986) 0.97
Elimination of beta-hexachlorocyclohexane in occupationally exposed persons. J Toxicol Environ Health (1997) 0.97
Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study. Onkologie (2005) 0.97
Inhibition of complement activation by natural sulfated polysaccharides (fucans) from brown seaweed. Mol Immunol (1994) 0.97
Health costs of occupational disease in New York State. Am J Ind Med (1989) 0.97
Clinical symptoms and DNA repair characteristics of xeroderma pigmentosum patients from Germany. Cancer Res (1991) 0.97
Corticosteroid-induced chemotherapy resistance in urological cancers. Cancer Biol Ther (2006) 0.97
Evidence for the role of CR1 (CD35), in addition to CR2 (CD21), in facilitating infection of human T cells with opsonized HIV. Scand J Immunol (1993) 0.96
One-year survival and neurological outcome after pediatric cardiopulmonary resuscitation. Intensive Care Med (2002) 0.96
Substance use and sexual risk behaviour among HIV-positive men who have sex with men in specialized out-patient clinics. HIV Med (2012) 0.96
Differential effects of the stimulation of complement receptors CR1 (CD35) and CR2 (CD21) on cell proliferation and intracellular Ca2+ mobilization of chronic lymphocytic leukemia B cells. J Immunol (1991) 0.96
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer (2010) 0.96
Allelic imbalance on chromosome 13q: evidence for the involvement of BRCA2 and RB1 in sporadic breast cancer. Cancer Res (1996) 0.96
Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol (2004) 0.95
Localization of the chaperone domain of FKBP52. J Biol Chem (2001) 0.95